文献速递肥胖与代谢综合征性腺与生殖内分泌

3期体重管理药物试验生殖结局注册的横断面元研究

Reproductive Outcome Registration in Phase 3 Weight‐Management Pharmacotherapy Trials: A Cross‐Sectional Meta‐Research Study
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-11-04

该研究横断面分析截至2026年8月31日ClinicalTrials.gov注册的230项成人3期体重管理药物试验,仅2项(0.87%)注册了生殖结局指标,而33项注册了体成分指标。男性生殖内分泌或精液指标在228项试验中均未注册。提示公开注册证据存在缺口,而非未测量。

要点

  • 230项3期体重管理药物试验中仅2项注册生殖结局,均为非工业赞助的多囊卵巢综合征人群。
  • 228项入组男性的试验均未注册男性性腺内分泌或精液指标。
  • 33项注册体成分的试验中31项无生殖结局注册,提示注册证据缺口。

核心结论

  • 在ClinicalTrials.gov注册的成人3期体重管理药物试验中,符合条件的生殖结局注册极为罕见,包括33项注册体成分的试验中有31项未注册生殖结局。
  • 这提示公开注册证据存在缺口,而非未进行测量;对已开展的生殖评估进行注册可提高其可发现性。

研究设计与样本

  • 横断面元研究,检索ClinicalTrials.gov截至2026年8月31日注册的记录。
  • 纳入标准为随机对照3期或2/3期试验,注册最低年龄≥18岁,药物干预,体重或BMI为主要结局,且注册体重相关疾病。
  • 共纳入230项试验(91个研发项目;3711项注册结局指标),使用已发表词典对注册结局字段分类。
  • 分析采用精确Clopper-Pearson区间和配对计数;项目层面、机制和年龄放宽分析为事后分析。

主要发现

  • 230项试验中仅2项注册任何生殖结局指标(0.87%,95% CI:0.11–3.11),均为多囊卵巢综合征人群且为非工业赞助。
  • 227项无生殖适应症的试验中无一项注册生殖结局指标。
  • 228项入组男性的试验中无一项注册具名男性性腺内分泌或精液指标(0/228,95% CI:0.00–1.60)。
  • 在基于胰高血糖素样肽-1(GLP-1)药物的试验中,生殖结局注册为2/152(1.32%)。
  • 33项试验注册体成分,其中31项无任何生殖结局指标,且无反向情况;项目层面为22项对0项。

临床怎么用

  • 内分泌科医生在评估体重管理药物试验证据时,需注意生殖结局在公开注册中罕见,不能仅凭注册信息判断是否存在生殖安全性评估。
  • 对于育龄期或关注生殖健康的患者,处方体重管理药物时应主动查阅全文学术文献或监管文件,而非依赖试验注册记录。

局限性

  • 研究仅基于ClinicalTrials.gov注册记录,未评估实际测量或发表文献中的生殖结局。
  • 纳入标准限定为注册主要结局含体重或BMI的3期或2/3期试验,可能遗漏其他设计。
  • 项目层面、机制和年龄放宽分析为事后分析,解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Aims To quantify registered reproductive outcome measures in women and men in adult Phase 3 weight-management pharmacotherapy trials and compare them with registered body-composition measures. Materials and Methods Cross-sectional meta-research study of ClinicalTrials.gov records as registered on 31 August 2026. Eligible trials were randomised, controlled, Phase 3 or 2/3, with registered minimum age ≥ 18 years, a pharmacological intervention, weight or BMI as a registered primary outcome and a weight-related registered condition. Registered outcome fields were classified with a published dictionary. Analyses used exact Clopper–Pearson intervals and paired counts; programme-level, mechanism and age-relaxed analyses were post hoc. Results Of 230 trials (91 development programmes; 3711 registered outcome measures), two registered any reproductive outcome measure (0.87%, 95% CI: 0.11–3.11), both in polycystic ovary syndrome populations with non-industry sponsors; none of 227 trials without a reproductive indication did. No trial enrolling men registered a named male gonadal-endocrine or semen measure (0/228, 95% CI: 0.00–1.60). Among trials of glucagon-like peptide-1-based agents it was 2/152 (1.32%). Body composition was registered in 33 trials, 31 without any reproductive measure and none the reverse; at programme level, 22 versus none. Admitting trials with minimum age below 18 years gave 7/254 (2.76%), including two industry trials registering gonadal hormones in adolescent safety panels. Conclusions Qualifying reproductive outcomes were rarely registered in adult Phase 3 weight-management pharmacotherapy trials on ClinicalTrials.gov, including 31 of 33 trials registering body composition. This identifies a gap in publicly registered evidence, not absence of measurement; registering reproductive assessments where undertaken would improve their discoverability.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Reproductive Outcome Registration in Phase 3 Weight‐Management Pharmacotherapy Trials: A Cross‐Sectional Meta‐Research Study

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。